Neurocrine Biosciences Presents Data At ECE 2024, The CAHtalyst Program In Congenital Adrenal Hyperplasia And Study Data For Modified-Release Hydrocortisone In Primary Adrenal Insufficiency And CAH
Neurocrine Biosciences Presents Data At ECE 2024, The CAHtalyst Program In Congenital Adrenal Hyperplasia And Study Data For Modified-Release Hydrocortisone In Primary Adrenal Insufficiency And CAH
- CAHtalyst Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults
- Phase 2 Study for Modified-Release Hydrocortisone in Adults with Adrenal Insufficiency Demonstrated Participants Achieved Physiological Morning Cortisol Levels after 4 Weeks
- Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Adults with CAH Demonstrated Reduction in Median Daily Hydrocortisone Dose and an Increase in Responders at Levels ≤ 25 mg/day
-Cahtalyst 第 3 階段的基線特徵凸顯了當前 CAH 治療模式在兒童、青少年和成人中的侷限性
-針對腎上腺功能不全成人的緩釋氫化可的松的二期研究表明，參與者在4周後達到了生理晨間皮質醇水平
-對患有CAH的成年人緩釋氫化可的松的松的3期擴展研究數據顯示，氫化可的松的日平均劑量有所降低，反應者在≤25 mg/天的水平上有所增加
SAN DIEGO, May 14, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented baseline data from the CAHtalyst Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH), and modified-release hydrocortisone (Chronocort) data for a Phase 2 clinical study (CHAMPAIN) in participants with primary adrenal insufficiency and in a Phase 3 extension study in CAH. These data, along with several additional posters were presented at the European Congress of Endocrinology 2024 meeting in Stockholm.
聖地亞哥，2024年5月14日 /PRNewswire/ — Neurocrine Biosciences, Inc.（納斯達克股票代碼：NBIX）和神經分泌生物科學公司Diurnal Ltd. 公佈了CahtAlyst對先天性腎上腺增生（CAH）和緩釋氫化可的松（Chronocort）患者進行crinecerfont的3期研究的基準數據一項針對原發性腎上腺功能不全受試者的2期臨床研究（CHAMPAIN）和CAH的3期延期研究的數據。這些數據以及其他幾張海報已在斯德哥爾摩舉行的2024年歐洲內分泌學大會會議上公佈。